Compare ASST & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASST | DBVT |
|---|---|---|
| Founded | 2020 | 2002 |
| Country | United States | France |
| Employees | 28 | 90 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 2022 | 2014 |
| Metric | ASST | DBVT |
|---|---|---|
| Price | $18.16 | $18.19 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 7 |
| Target Price | $23.50 | ★ $32.04 |
| AVG Volume (30 Days) | ★ 3.3M | 146.9K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 82.56 | 10.26 |
| EPS | N/A | ★ N/A |
| Revenue | $633,489.00 | ★ $5,636,000.00 |
| Revenue This Year | $294.91 | $35.04 |
| Revenue Next Year | $12.16 | $2,360.78 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 128.67 | 35.77 |
| 52 Week Low | $0.49 | $7.53 |
| 52 Week High | $18.54 | $26.19 |
| Indicator | ASST | DBVT |
|---|---|---|
| Relative Strength Index (RSI) | 63.09 | 35.99 |
| Support Level | $14.31 | $16.49 |
| Resistance Level | N/A | $21.61 |
| Average True Range (ATR) | 1.30 | 0.76 |
| MACD | -0.05 | -0.16 |
| Stochastic Oscillator | 69.09 | 3.15 |
Strive Inc is a structured finance company and institutional asset manager focused on disciplined capital allocation and long term value creation. The company has adopted bitcoin as its hurdle rate for capital deployment because of its fiduciary duty to maximize long-term value for stockholders, and compounding purchasing power over time. It operates in two reportable operating segments: the Asset Management segment, which provides investment advisory services and the Corporate & Other segment, which includes the company's bitcoin treasury operations. The majority of the revenue is derived from the Asset Management segment.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.